FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Lars Frison

Research Profile

Chemicals & Drugs

Procedures

Phenomena

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Marco J D Tangelder; Lars Frison; Douglas Weaver; Robert G Wilcox; Anders Bylock; Håkan Emanuelsson; Peter Held; Jonas Oldgren
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
Gunnar Fager; Marie Cullberg; Maria Eriksson-Lepkowska; Lars Frison; Ulf G Eriksson
Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
Ulf G Eriksson; Ulf Bredberg; Kristina Gislén; Linda C Johansson; Lars Frison; Martin Ahnoff; David Gustafsson
Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Lars Frison (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Marco J D Tangelder; Lars Frison; Douglas Weaver; Robert G Wilcox; Anders Bylock; Håkan Emanuelsson; Peter Held; Jonas Oldgren
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
American heart journal 2008;155(2):382-7.
2003: Gunnar Fager; Marie Cullberg; Maria Eriksson-Lepkowska; Lars Frison; Ulf G Eriksson
Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
European journal of clinical pharmacology 2003;59(4):283-9.
2003: Ulf G Eriksson; Ulf Bredberg; Kristina Gislén; Linda C Johansson; Lars Frison; Martin Ahnoff; David Gustafsson
Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
European journal of clinical pharmacology 2003;59(1):35-43.
2003: Bengt I Eriksson; Giancarlo Agnelli; Alexander T Cohen; Ola E Dahl; Patrick Mouret; Nadia Rosencher; Christina Eskilson; Ingela Nylander; Lars Frison; Mats Ogren
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Thrombosis and haemostasis 2003;89(2):288-96.
2003: Henry Eriksson; Karin Wåhlander; David Gustafsson; Lennart Welin; Lars Frison; Sam Schulman
A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.
Journal of thrombosis and haemostasis : JTH 2003;1(1):41-7.
2003: Eva Bredberg; Tommy B Andersson; Lars Frison; Anneli Thuresson; Susanne Johansson; Maria Eriksson-Lepkowska; Marita Larsson; Ulf G Eriksson
Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
Clinical pharmacokinetics 2003;42(8):765-77.
2003: Karin Wåhlander; Maria Eriksson-Lepkowska; Lars Frison; Gunnar Fager; Ulf G Eriksson
No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Clinical pharmacokinetics 2003;42(8):755-64.
2003: Ulf G Eriksson; Susanne Johansson; Per-Ola Attman; Henrik Mulec; Lars Frison; Gunnar Fager; Ola Samuelsson
Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
Clinical pharmacokinetics 2003;42(8):743-53.
2003: Ulf G Eriksson; Jaap W Mandema; Mats O Karlsson; Lars Frison; Per Olsson Gisleskog; Ulrika Wählby; Bengt Hamrén; David Gustafsson; Bengt I Eriksson
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
Clinical pharmacokinetics 2003;42(7):687-701.
2003: Linda C Johansson; Lars Frison; Ulrika Logren; Gunnar Fager; David Gustafsson; Ulf G Eriksson
Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Clinical pharmacokinetics 2003;42(4):381-92.
2002: Bengt I Eriksson; David Bergqvist; Peter Kälebo; Ola E Dahl; Siv Lindbratt; Anders Bylock; Lars Frison; Ulf G Eriksson; Lennart Welin; David Gustafsson
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
Lancet 2002;360(9344):1441-7.
2002: Karin Wåhlander; Göran Larson; Tomas L Lindahl; C Andersson; Lars Frison; David Gustafsson; Anders Bylock; Bengt I Eriksson
Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.
Thrombosis and haemostasis 2002;87(4):580-5.
2002: Bengt I Eriksson; Mats Ogren; Ulf G Eriksson; Peter Kälebo; Lennart Ahnfelt; Sven Björkström; Ake Sjöstedt; Agnetha Folestad; Ann-Christin Arfwidsson; Christine Sareyko Elvander; Lars Frison
Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies.
Thrombosis research 2002;105(5):371-8.
2002: Troy C Sarich; Ulf G Eriksson; Christer Mattsson; Michael Wolzt; Lars Frison; Gunnar Fager; David Gustafsson
Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.
Thrombosis and haemostasis 2002;87(2):300-5.
2002: Bengt I Eriksson; Ann-Christin Arfwidsson; Lars Frison; Ulf G Eriksson; Anders Bylock; Peter Kälebo; Gunnar Fager; David Gustafsson
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Thrombosis and haemostasis 2002;87(2):231-7.
1999: Henry Eriksson; Ulf G Eriksson; Lars Frison; P O Hansson; Peter Held; Margareta Holmström; A Hägg; T Jonsson; Leif Lapidus; B Leijd; Dick Stockelberg; U Säfwenberg; A Taghavi; M Thorsén
Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Thrombosis and haemostasis 1999;81(3):358-63.